24/7 Market News Snapshot 07 October, 2025 – Anixa Biosciences, Inc. (NASDAQ:ANIX)

October 7, 2025

DENVER, Colo., 07 October, 2025 (www.247marketnews.com) – (NASDAQ:ANIX) are discussed in this article.
Anixa Biosciences, Inc. is experiencing a remarkable uptick in market activity, having opened at $3.40 and currently trading at $3.595, reflecting an increase of 10.62% from the previous close of $3.25. This surge is indicative of strong investor interest, as evidenced by a current trading volume of 523.98K shares. The sharp rise in stock price points towards positive sentiment surrounding the company, which traders should continue to monitor, especially in relation to key support levels around $3.40 and resistance near the $3.60 mark.

Driving this enthusiasm is Anixa’s recent announcement regarding a significant milestone in its breast cancer vaccine clinical trial. The company has completed the final patient visit for the Phase 1 trial, which aims to harness the immune system to recognize and eliminate breast cancer cells preemptively. This innovative vaccine, developed in collaboration with Cleveland Clinic, is supported by a grant from the U.S. Department of Defense and represents a pivotal advancement in cancer treatment.

The trial comprised 35 women across varied cohorts, including those previously treated for triple-negative breast cancer and patients receiving concurrent checkpoint inhibitor therapies. Initial results demonstrate promise, with over 70% of participants showing immune responses, suggesting the vaccine’s potential effectiveness.

With data analysis now in progress, Anixa is preparing to submit its findings to both the Department of Defense and the U.S. Food and Drug Administration (FDA), and aims to present comprehensive results at the upcoming San Antonio Breast Cancer Symposium in December 2025. Dr. G. Thomas Budd from Cleveland Clinic has highlighted the interim data’s safety and immune response efficacy, while Dr. Amit Kumar, CEO of Anixa, is optimistic about the implications of these findings for cancer immunotherapy. The company’s focus on tackling challenging cancer types through collaboration with esteemed research institutions positions it at the forefront of oncology advancements.

Related news for (ANIX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.